857TiP An open-label, multicenter, phase II study of CLR 131 in patients with relapsed or refractory (R/R) select B-cell malignancies (CLOVER-1) and expansion cohort in patients with waldenstrom macroglobulinemia (CLOVER-WaM)

Phospholipid ethers (PLE) provide an innovative approach to preferentially target cancer cells by capitalizing on their increased number/size of lipid rafts. PLE are designed to possess high affinity to lipid rafts which upon binding results in internalization and the ability to deliver an attached warhead to the cytosol. CLR 131 is a novel PLE conjugated to I-131, which was chosen due to its 8-day half-life and well-established efficacy in...